Publications by authors named "Keith Saylor"

Claim this Profile
A
A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD.
Janet K Johnson, Tesfaye Liranso, Keith Saylor, Gabriela Tulloch, Toyin Adewole

J Atten Disord· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of the Impulsive Aggression Diary in Adolescents with Attention-Deficit/Hyperactivity Disorder.
Gianpiera Ceresoli-Borroni, Tesfaye Liranso, Scott T Brittain, Daniel F Connor, Christopher J Evans, Keith E Saylor

J Child Adolesc Psychopharmacol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maladaptive Aggression: With a Focus on Impulsive Aggression in Children and Adolescents.
Daniel F Connor, Jeffrey H Newcorn, Keith E Saylor, Birgit H Amann, Lawrence Scahill

J Child Adolesc Psychopharmacol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impulsive Aggression as a Comorbidity of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents.
Keith E Saylor, Birgit H Amann

J Child Adolesc Psychopharmacol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential response profiles in children and adolescents with attention-deficit/hyperactivity disorder: treatment with atomoxetine.
Linda A Wietecha, Shufang Wang, Keith E Saylor, Kathleen A Day, Sheng Hu Wu

Clin Pediatr (Phila)· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trials.
Philip Asherson, Chris Bushe, Keith Saylor, Yoko Tanaka, Walter Deberdt

J Psychopharmacol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Participant-perceived quality of life in a long-term, open-label trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
Ann C Childress, Andrew J Cutler, Keith Saylor, Maria Gasior, Mohamed Hamdani

J Child Adolesc Psychopharmacol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study.
Lenard A Adler, Bryan Dirks, Patrick Deas, Aparna Raychaudhuri, Matthew Dauphin, Keith Saylor

BMC Psychiatry· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atomoxetine once daily for 24 weeks in adults with attention-deficit/hyperactivity disorder (ADHD): impact of treatment on family functioning.
Linda Wietecha, Joel Young, Dustin Ruff, David Dunn, Robert L Findling, Keith Saylor

Clin Neuropharmacol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
Robert L Findling, Andrew J Cutler, Keith Saylor, Maria Gasior, Mohamed Hamdani

J Child Adolesc Psychopharmacol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of atomoxetine on executive function impairments in adults with ADHD.
Thomas E Brown, James Holdnack, Keith Saylor, Lenard Adler, Thomas Spencer

J Atten Disord· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD.
Keith Saylor, David W Williams, Kory J Schuh, Linda Wietecha, Michael Greenbaum

Curr Med Res Opin· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post hoc analysis: early changes in ADHD-RS items predict longer term response to atomoxetine in pediatric patients.
Stan L Block, David Williams, Craig L Donnelly, David W Dunn, Keith E Saylor

Clin Pediatr (Phila)· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the adult ADHD investigator symptom rating scale (AISRS).
Thomas J Spencer, Lenard A Adler, Meihua Qiao, Keith E Saylor, Thomas E Brown

J Atten Disord· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.
Lenard A Adler, Thomas Spencer, Thomas E Brown, James Holdnack, Keith Saylor

J Clin Psychopharmacol· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emotional expression in children treated with ADHD medication: development of a new measure.
Amy R Perwien, Christopher J Kratochvil, Douglas Faries, Brigette Vaughan, Joan Busner, Keith E Saylor

J Atten Disord· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Life Participation Scale for Attention-Deficit/Hyperactivity Disorder--Child Version: psychometric properties of an adaptive change instrument.
Keith Saylor, Curt Buermeyer, Virginia Sutton, Douglas Faries, Sajjad Khan

J Child Adolesc Psychopharmacol· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment.
Thomas J Spencer, Christopher J Kratochvil, R Bart Sangal, Keith E Saylor, Charles E Bailey

J Child Adolesc Psychopharmacol· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose atomoxetine treatment of ADHD in youths with limited response to standard doses.
Christopher J Kratochvil, David Michelson, Jeffrey H Newcorn, Margaret D Weiss, Joan Busner, Keith E Saylor

J Am Acad Child Adolesc Psychiatry· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine.
Lenard A Adler, Virginia K Sutton, Rodney J Moore, Anthony P Dietrich, Frederick W Reimherr, Keith E Saylor

J Clin Psychopharmacol· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of the going places program on early adolescent substance use and antisocial behavior.
Bruce Simons-Morton, Denise Haynie, Keith Saylor, Aria Davis Crump, Rusan Chen

Prev Sci· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact analysis and mediation of outcomes: the Going Places program.
Bruce Simons-Morton, Denise Haynie, Keith Saylor, Aria Davis Crump, Rusan Chen

Health Educ Behav· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.
Douglas K Kelsey, Calvin R Sumner, Charles D Casat, Daniel L Coury, Humberto Quintana, Keith E Saylor

Pediatrics· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adaptive changes related to medication treatment of ADHD: listening to parents of children in clinical trials of a novel nonstimulant medication.
Keith E Saylor, Curtis M Buermeyer, Thomas J Spencer, Russell A Barkley

J Clin Psychiatry· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.
David Michelson, Albert J Allen, Joan Busner, Charles Casat, David Dunn, Keith Saylor

Am J Psychiatry· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis